Patents by Inventor George L. Sing
George L. Sing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9084787Abstract: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: March 11, 2013Date of Patent: July 21, 2015Assignee: STEMNION, INC.Inventors: George L Sing, Diana L Clarke, Vivienne S Marshall
-
Publication number: 20150150915Abstract: The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including novel immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.Type: ApplicationFiled: December 1, 2014Publication date: June 4, 2015Applicant: STEMNION, INC.Inventors: Larry R. Brown, George L. Sing, Howard C. Wessel
-
Publication number: 20150072427Abstract: The invention is directed to methods for reprogramming somatic cells to a less differentiated state. In particular, the invention is directed to methods for reprogramming amnion epithelial cells (AEC) including amnion-derived cells (ADC) and Amnion-derived Multipotent Progenitor cells (AMP cells) to a less differentiated state. The invention is further directed to compositions comprising reprogrammed AEC, ADC and AMP cells, and uses thereof.Type: ApplicationFiled: November 20, 2014Publication date: March 12, 2015Applicant: Stemnion, Inc.Inventor: George L. Sing
-
Publication number: 20150051147Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: August 12, 2014Publication date: February 19, 2015Applicant: STEMNION, INC.Inventors: George L. Sing, Randall G. Rupp, David L Steed
-
Publication number: 20150025007Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: August 1, 2014Publication date: January 22, 2015Inventors: Charlotte A. Emig, Catherine J. Trumpower, George L. Sing
-
Publication number: 20140341860Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.Type: ApplicationFiled: May 13, 2014Publication date: November 20, 2014Applicant: STEMNION, INC.Inventors: Donna M. Olejniczak, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 8883136Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).Type: GrantFiled: March 5, 2013Date of Patent: November 11, 2014Assignee: Stemnion, Inc.Inventors: George L Sing, David L Steed
-
Publication number: 20140271773Abstract: The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: STEMNION, INC.Inventors: Larry R. Brown, George L. Sing
-
Publication number: 20140255355Abstract: The invention is directed to methods for treating blepharitis. The invention is further directed to reducing inflammation associated with blepharitis. The invention is further directed to methods for treating blepharitis and/or reducing inflammation associated with blepharitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: March 3, 2014Publication date: September 11, 2014Applicant: STEMNION, INC.Inventor: George L. Sing
-
Publication number: 20140255904Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: March 3, 2014Publication date: September 11, 2014Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 8822415Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: July 19, 2013Date of Patent: September 2, 2014Assignee: Stemnion, Inc.Inventors: Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Publication number: 20140079688Abstract: The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface. Such methods utilize novel compositions including, but not limited to, trophic factor secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicant: Stemnion, Inc.Inventor: George L. Sing
-
Patent number: 8642547Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).Type: GrantFiled: January 7, 2012Date of Patent: February 4, 2014Assignee: Stemnion, Inc.Inventors: George L. Sing, David L. Steed
-
Publication number: 20140017193Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: September 17, 2013Publication date: January 16, 2014Applicant: Stemnion, Inc.Inventors: George L. Sing, Vivienne S. Marshall
-
Publication number: 20130302307Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: July 19, 2013Publication date: November 14, 2013Inventors: Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Patent number: 8475788Abstract: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: November 27, 2007Date of Patent: July 2, 2013Assignee: Stemnion, Inc.Inventors: George L. Sing, Diana L. Clarke, Vivienne S. Marshall
-
Publication number: 20130040880Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: October 17, 2012Publication date: February 14, 2013Applicant: Stemnion, Inc.Inventors: Vivienne S. Marshall, Catherine J. Trumpower, Charlotte A. Smith, George L. Sing, Linda O. Palladino
-
Publication number: 20120322731Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: August 28, 2012Publication date: December 20, 2012Applicant: STEMNION, INC.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Patent number: 8278417Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: April 10, 2012Date of Patent: October 2, 2012Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Publication number: 20120230941Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: May 23, 2012Publication date: September 13, 2012Inventors: George L. Sing, Vivienne S. Marshall, Diana L. Clarke